Amid concerns that the blood supply was contaminated the NIH officials announced they'd already held a conference on the issue. The Whittemore Peterson Institute rapidly conferred a new name for what it believes are a cadre of XMRV diseases - XAND (X Related Neuroimmune Disorder).
Questions were quickly raised concerning prevalence, transmission, testing, treatment, etc.
Check out the below sections for more information on this startling find. The first page - a very long - contains an overview of what I've learned thus far. Much of it, of course, is subject to change.
Immense congratulations and thanks, of course, go to the WPI.
Check out the below sections for more information on this startling find. The first page - a very long - contains an overview of what I've learned thus far. Much of it, of course, is subject to change.
Game Changer:the overview: what happened, prevalence, transmission, diagnosis, related research, etc. - http://aboutmecfs.org/Rsrch/XMRV.aspx
Treatment Options- potential treatment options - http://aboutmecfs.org/Rsrch/XMRVIntro.aspx
Resource Page- links to articles, blogs, websites - http://aboutmecfs.org/Rsrcs/XMRVResources.aspx
Discussion Center- Discuss XMRV/XAND here - http://forums.aboutmecfs.org/forumdisplay.php?f=54
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Select list topic options at http://www.co-cure.org/topics.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
